Targets › CTLA4
71 programs from 59 companies in 534 trials: 353 Phase 2, 117 Phase 1, 60 Phase 3, 4 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.
Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. (UniProt, P16410)
Open in Phaseline: the race on CTLA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Akeso | Cadonilimab (AK104) Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor | PDCD1, CTLA4 | Phase 3 | Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) … | Nov 2026 |
| Shandong Cancer Hospital and Institute | Iparomlimab CTLA-4 inhibitor | CTLA4 | Phase 3 | Local Advanced Rectal Cancer; Rectal Malignant Neoplasms; Cervical Cancer | Nov 2026 |
| OncoC4 | ONC-392 (Gotistobart) anti-CTLA4 monoclonal antibody | CTLA4 | Phase 3 | Non Small Cell Lung Cancer; Ovarian Cancer; Metastatic Castration-resistant Prostate Cancer | Nov 2026 |
| AstraZeneca | Tremelimumab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 3 | Small Cell Lung Cancer; Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Non Small Cell Lung Carcinoma NSCLC … | Nov 2026 |
| AstraZeneca | Volrustomig (MEDI5752) CTLA-4/PD-1 bispecific antibody | CTLA4, PDCD1, TIGIT | Phase 3 | Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma … | Jan 2027 |
| Bristol-Myers Squibb | Ipilimumab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 3 | Urothelial Cancer; Renal Cell Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer … | Feb 2027 |
| Merck & Co. (MSD) | Quavonlimab CTLA-4 inhibitor | CTLA4 | Phase 3 | Carcinoma, Renal Cell | Apr 2027 |
| Tongji Hospital | Iparomlimab and Tuvonralimab (QL1706) Bispecific antibody targeting PD-1 and CTLA-4 | CTLA4, PDCD1 | Phase 3 | Ovarian Clear Cell Carcinoma; Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Jun 2027 |
| Innovent Biologics (Suzhou) | IBI310 CTLA-4 inhibitor | CTLA4 | Phase 3 | MSI-H | Apr 2028 |
| Summit Therapeutics | Ivonescimab Dose 1 TIGIT inhibitor | TIGIT, CTLA4 | Phase 3 | Non-Small Cell Lung Cancer; Metastatic Urothelial Carcinoma | Apr 2028 |
| UNICANCER | Reduced dose intensity of IO Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor | PDCD1, CD274, CTLA4 | Phase 3 | Lung Cancer Metastatic | May 2029 |
| Xijing Hospital | IBI-310 CTLA-4 inhibitor | CTLA4 | Phase 2 | MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma | Nov 2026 |
| Sichuan Baili Pharmaceutical | SI-B003 PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer … | Nov 2026 |
| Hebei Medical University Fourth Hospital | Iparomlimab CTLA-4 inhibitor | CTLA4, TIGIT | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC); AFP Gastric or Gastroesophageal Junction Adenocarcinoma; Colon Cancer | Dec 2026 |
| Jiang Long | Adebelimab CTLA-4 monoclonal antibody | CTLA4 | Phase 2 | Pancreatic Cancer Metastatic to Liver | Dec 2026 |
| Sir Run Run Shaw Hospital | Aiparolitoworixureli injection PD-1/CTLA-4 bispecific monoclonal antibody; dual checkpoint inhibitor blocking PD-1 and CT | PDCD1, CTLA4 | Phase 2 | Rectal Cancer | Dec 2026 |
| Ruijin Hospital | Iparomlimab and Tuvonralimab (QL1706) PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Gastric Adenocarcinoma | Dec 2026 |
| First Affiliated Hospital of Zhejiang University | PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection) PD-1/CTLA-4 dual checkpoint inhibitor antibody | PDCD1, CTLA4 | Phase 2 | Bile Duct Carcinoma | Dec 2026 |
| Shandong Provincial Hospital | QL1706 (Iparomlimab and Tuvonralimab) Combination of PD-1 inhibitor (Iparomlimab) and CTLA-4 inhibitor (Tuvonralimab) | PDCD1, CTLA4 | Phase 2 | Locally Advanced Resectable Esophageal Squamous Cell Carcinoma; Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | PD-1/VEGF dual antibody PD-1 inhibitor and anti-VEGF antibody | PDCD1, VEGFA, CTLA4 | Phase 2 | Glioblastoma | Jan 2027 |
| Zhongnan Hospital | Tuvonralimab (QL1706) CTLA-4 inhibitor | CTLA4 | Phase 2 | Rectal Cancer Patients | Jan 2027 |
| Peking University Cancer Hospital & Institute | QL1706 Anti-PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Esophageal Squamous Cell Carcinoma | Mar 2027 |
| Sun Yat-sen University | Iparomlimab and Tuvonralimab (QL1706) Dual PD-1/CTLA-4 combination antibody | CTLA4, PDCD1 | Phase 2 | Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer; Bone and Soft Tissue Tumors; BRAF V600 Colorectal Cancer; Hepatocellular Carcinoma (HCC) … | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | lparomlimab and Tuvonralimab Injection (QL1706) Anti-PD-1/CTLA-4 combined antibody | PDCD1, CTLA4 | Phase 2 | Endometrial Adenocarcinoma; Metastatic Pancreatic Cancer; HCC; Breast Cancer | Apr 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aitua Combination Antibody (QL1706) PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | High-grade Serous Ovarian Cancer (HGSOC) | May 2027 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | tirilizumab CTLA-4 inhibitor | CTLA4 | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Jun 2027 |
| Tianjin Medical University Second Hospital | Tagitanlimab anti-CTLA-4 monoclonal antibody | CTLA4 | Phase 2 | Prostate Cancer (Adenocarcinoma) | Jun 2027 |
| Xijing Hospital | Iparomlimab/Tuvonralimab (QL1706) Bispecific antibody targeting PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Locally Advanced Cervical Cancer | Jul 2027 |
| MacroGenics | Lorigerlimab Bispecific DART protein binding PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic Adenocarcinoma | Jul 2027 |
| Ruijin Hospital | Apalulizumab Dual-function antibody targeting both PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Pancreatic Adenocarcinoma Locally Advanced | Aug 2027 |
| Ruijin Hospital | Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) Bispecific antibody targeting PD-1 and CTLA-4 immune checkpoints | PDCD1, CTLA4 | Phase 2 | Pancreatic Adenocarcinoma Locally Advanced | Aug 2027 |
| The First Affiliated Hospital of Zhengzhou University | cadonilizumab PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Esophageal Squamous Cell Carcinoma | Aug 2027 |
| Agenus | Botensilimab Anti-CTLA-4 monoclonal antibody | CTLA4 | Phase 2 | Advanced Melanoma; Metastatic Colorectal Cancer; Gastric Cancer; Colorectal Cancer Metastatic … | Sep 2027 |
| Yongxu Jia | Iparomlimab and Tuvonralimab Injection (QL1706) CTLA-4 and PD-1 dual checkpoint inhibitor | CTLA4, PD-1 | Phase 2 | Gastroesophageal Junction Adenocarcinoma | Sep 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Iparomlimab PD-1 and CTLA-4 inhibitor | PDCD1, CTLA4 | Phase 2 | Esophageal Cancer | Sep 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Iparomlimab and Tuvonralimab (QL1706) PD-1 and CTLA-4 dual checkpoint inhibitor | PDCD1, CTLA4 | Phase 2 | HCC - Hepatocellular Carcinoma | Oct 2027 |
| Qilu Hospital of Shandong University | Iparomlimab and Tuvonralimab (QL1706) Dual CTLA-4 and PD-1 inhibitor | CTLA4, PD-1 | Phase 2 | HER2 Negative | Oct 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Iparomlimab/Tuvonralimab Bifunctional mabpair product of anti-PD-1 and anti-CTLA-4 antibodies | PDCD1, CTLA4 | Phase 2 | LOCALLY ADVANCED CERVICAL CANCERS | Nov 2027 |
| Lei Liu | Ivonescimab Bispecific antibody targeting PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2027 |
| Jiangsu Cancer Institute & Hospital | Tuvonralimab CTLA-4 inhibitor | CTLA4 | Phase 2 | NSCLC | Dec 2027 |
| Nanfang Hospital, Southern Medical University | Iparomlimab and Tuvonralimab Injection (QL1706) PD-1 and CTLA-4 dual inhibitor | PDCD1, CTLA4 | Phase 2 | Hepatecellular Carcinoma | Dec 2027 |
| Innovent Biopharmaceutical Technology (Hangzhou) | IBI310 CTLA-4 inhibitor | CTLA4 | Phase 2 | Hepatocellular Carcinoma (HCC); Neuroendocrine Neoplasm; Gastric Cancer | Dec 2027 |
| The First Affiliated Hospital of Xiamen University | Iparomlimab/Tuvorlimab (QL-1706) CTLA-4 inhibitor | CTLA4 | Phase 2 | Locally Advanced Nasopharyngeal Carcinoma | Dec 2027 |
| Shanghai Zhongshan Hospital | Iparomlimab and Tuvonralimab (QL1706) Bifunctional monoclonal antibody composed of PD-1 inhibitor (IgG4) and CTLA-4 inhibitor (I | PDCD1, CTLA4 | Phase 2 | Biliary Tract Cancer (BTC) | Jun 2028 |
| Shanghai Pulmonary Hospital, Shanghai, China | IBI310 anti-CTLA-4 antibody | CTLA4 | Phase 2 | NSCLC Stage II | Jun 2028 |
| Second Affiliated Hospital of Nanchang University | Tuvonralimab CTLA-4 inhibitor | CTLA4 | Phase 2 | Cancer | Jun 2028 |
| Changhai Hospital | QL1706 Dual PD-1/CTLA-4 antibody | PDCD1, CTLA4 | Phase 2 | MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706 | Aug 2028 |
| Changhai Hospital | iparomlimab CTLA-4 inhibitor | CTLA4 | Phase 2 | MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706 | Aug 2028 |
| Tianjin Medical University Cancer Institute and Hospital | Iparomlimab/Tuvonralimab CTLA-4 and PD-1 inhibitor combination | CTLA4, PD-1 | Phase 2 | HCC - Hepatocellular Carcinoma | Aug 2028 |
| Obstetrics & Gynecology Hospital of Fudan University | Ivonescimab TIGIT inhibitor with bispecific antibody targeting TIGIT and PD-1 | PDCD1, CTLA4 | Phase 2 | Cervical Cancers | Aug 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | CTLA-4 antibody CTLA-4 immune checkpoint inhibitor | CTLA4 | Phase 2 | Lung Cancer | Dec 2028 |
| West China Hospital | Ivonescimab PD-1 and CTLA-4 dual inhibitor | PD-1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2028 |
| Kong Fanming | attilizumab CTLA-4 inhibitor | CTLA4 | Phase 2 | Non-Small Cell Lung Cancer | Dec 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | PD-1/PD-L1/CTLA-4 inhibitors PD-1, PD-L1, and CTLA-4 checkpoint inhibitors | PDCD1, CD274, CTLA4 | Phase 2 | Head/Neck Neoplasm | Jan 2029 |
| Sun Yat-sen University | Ipromlimab CTLA-4 inhibitor | CTLA4 | Phase 2 | Locally Advanced, Resectable | Jun 2029 |
| Fujian Cancer Hospital | Tuvonralimab CTLA-4 inhibitor | CTLA4 | Phase 2 | Locally Advanced Cervical Cancer | Sep 2029 |
| Immune Oncology Research Institute | Botensilimab Fc-engineered monoclonal antibody targeting CTLA-4 | CTLA4 | Phase 2 | Non-small Cell Lung Cancer | Apr 2030 |
| Innovent Biopharmaceutical Technology (Hangzhou) | Ipilimumab (N01) Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 2 | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Dec 2031 |
| Xencor | vudalimab (XmAb20717) Bispecific monoclonal antibody targeting CTLA-4 and TIGIT | CTLA4, TIGIT | Phase 2 | Ovarian Cancer | – |
| Shanghai Zhongshan Hospital | cardonilizumab PD-1 and CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 1 | Biliary Tract Cancer | Dec 2026 |
| Shanghai Henlius Biotech | HLX13 CTLA-4 inhibitor (anti-CTLA-4 monoclonal antibody biosimilar) | CTLA4 | Phase 1 | Hepatocellular Carcinoma (HCC) | Dec 2026 |
| Fudan University | IBI110 LAG-3 inhibitor | CTLA4 | Phase 1 | Head and Neck Cancer | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Antithymocyte globulin (ATG) Polyclonal antibody targeting T lymphocytes; immunosuppressant | CTLA4, CD2, CD3, CD4, CD8 | Phase 1 | Myeloid Diseases; Hematologic Malignancies | May 2027 |
| Adagene | ADG126 anti-CTLA-4 monoclonal antibody | CTLA4 | Phase 1 | Advanced/Metastatic Solid Tumors; Locally Advanced Colorectal Cancer | Jun 2027 |
| ImmunoGenesis | Zalifrelimab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 1 | Metastatic Prostate Cancer; Metastatic Soft Tissue Sarcoma; Diffuse Intrinsic Pontine Glioma | Oct 2027 |
| Revolution Medicines | Ivonescimab PD-1 and CTLA-4 dual antagonist | PD-1, CTLA4 | Phase 1 | Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma … | May 2029 |
| BioNTech SE | BNT316 anti-CTLA-4 antibody | CTLA4 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| InxMed (Shanghai) | Erfonrilimab (KN046) Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor | CTLA4, CD274 | Phase 1 | Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer | – |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | IMM27M Humanized Fc-engineered anti-CTLA-4 antibody | CTLA4 | Phase 1 | Advanced Solid Tumors | – |
| Nelum | Zalifrelimab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 1 | Pancreatic Ductal Adenocarcinoma | – |
Hepatocellular Carcinoma (19) Melanoma (12) Colorectal Cancer (11) Non-Small Cell Lung Cancer (10) Hepatocellular Carcinoma (HCC) (10) Non Small Cell Lung Cancer (9) Cervical Cancer (8) Head and Neck Squamous Cell Carcinoma (7) Non-small Cell Lung Cancer (7) Breast Cancer (6) Pancreatic Cancer (6) Metastatic Colorectal Cancer (6)
mixed (28), antibody (26), small molecule (10), protein or peptide (1)
Tianjin Medical University Cancer Institute and Hospital (3) Ruijin Hospital (3) AstraZeneca (2) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) Innovent Biopharmaceutical Technology (Hangzhou) (2) Shanghai Zhongshan Hospital (2) Second Affiliated Hospital of Guangzhou Medical University (2) Changhai Hospital (2) Xijing Hospital (2) Sun Yat-sen University (2) Shandong Cancer Hospital and Institute (1) Sichuan Baili Pharmaceutical (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Summit Therapeutics (1) Revolution Medicines (1) OncoC4 (1) Yongxu Jia (1) Bristol-Myers Squibb (1) Akeso (1) InxMed (Shanghai) (1)
PDCD1 (30) PD-1 (5) TIGIT (4) CD274 (3) CD2 (1) CD3 (1) CD4 (1) CD8 (1) GLP1R (1) ATP4A (1) ATP4B (1) FKBP1A (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.